Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
ANX005 First Potential Targeted Therapy for Guillain-Barré Syndrome Advancing Towards 1H 2025 BLA SubmissionANX007 First Potential ...